TechNotableSingle-sourceDeveloping
4.9
Hong Kong unveils first 5-year plan targeting biomedicine hub status
South China Morning PostLO·HK · CN·2 days ago
Hong Kong's SFC ordered a trading halt for Cloudbreak Pharma amid allegations its $78M IPO was manipulated to fabricate demand. The suspension signals heightened regulatory scrutiny of IPO practices in Hong Kong, potentially affecting market confidence in new listings. The investigation is ongoing, and the outcome remains uncertain.
Locations
Entities